Fudan University Researchers Update Knowledge of Tumors (TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity).

Researchers at Fudan University have developed a novel combination therapy involving low-dose cisplatin and a TLR7/8/9 agonist formulation to enhance antitumor immune responses. This therapy showed significant efficacy in abrogating established tumors in mouse models by promoting tertiary lymphatic structure formation and activating immune cells. The study suggests that this combination therapy has the potential to convert 'cold' tumors into 'hot' ones and induce robust antitumor immune responses in vivo. [Extracted from the article]